DOI QR코드

DOI QR Code

A case of persistent pulmonary hypertension of the newborn: Treatment with inhaled iloprost

Iloprost 흡입 투여로 치료한 신생아 폐고혈압 지속증 1예

  • Jang, Yoon Young (Department of Pediatrics, School of Medicine, Catholic University of Daegu) ;
  • Park, Hye Jin (Department of Pediatrics, School of Medicine, Catholic University of Daegu)
  • 장윤영 (대구가톨릭대학교 의과대학 소아과학교실) ;
  • 박혜진 (대구가톨릭대학교 의과대학 소아과학교실)
  • Received : 2009.05.25
  • Accepted : 2009.09.11
  • Published : 2009.10.15

Abstract

We report a case of a full-term neonate with persistent pulmonary hypertension who developed asphyxia after birth and was treated with iloprost. The neonate had persistent hypoxia and did not respond to supportive treatment. Because inhaled nitric oxide (iNO) was not available in our hospital, inhaled iloprost was administered via an endotracheal tube. This resulted in an immediate elevation of oxygen saturation. Echocardiography revealed the conversion of the right-to-left ductal shunt to the left-to-right one and a decrease of the right ventricular pressure. The use of inhaled iloprost did not cause any significant side effects. Here, we describe our experience where iloprost was used in a neonate with persistent pulmonary hypertension because the standard therapy with inhaled nitric oxide was not available.

신생아 폐고혈압 지속증은 치료가 힘들고 사망률이 높은 질환이나, 산화질소 흡입 치료가 시행된 이후 사망률의 많은 감소를 가져왔다. 그러나, 신생아 집중 치료실이 있는 병원이라도 이러한 산화질소 흡입 치료가 가능하지 않는 곳이 많고, 산화질소 투여에도 호전되지 않는 경우도 있다. 흡입 iloprost는 최근 원발성 혹은 이차성 폐고혈압 환자에서 사용이 늘고있는 폐동맥 확장제로, 신생아 폐고혈압 지속증에 사용한 증례가 외국에 보고된 바 있다. 환아는 출생시 심한 태변 착색과 출산 질식, 진행되는 저산소증을 보였으며, 신생아 폐고혈압 지속증으로 진단되었다. 환아는 지속적인 저산소증을 보였으며, 통상적인 지지 치료에도 호전되지 않았다. 당시 저자들의 병원에는 산화질소 흡입 치료가 가능하지 않아, iloprost 흡입 치료를 시도하였다. Iloprost 흡입 치료 이후 수시간 내에 산소 포화도가 증가하였으며, 심초음파상에는 동맥관을 통한 우좌 단락이 좌우로 바뀌었고, 우심실 압력이 감소하였다. Iloprost 흡입 치료를 하는 동안 특별한 부작용은 관찰되지 않았다. 저자들은 산화질소 흡입치료가 가능하지 않은 상황에서 신생아 폐고혈압 지속증 신생아의 치료로 iloprost 흡입 치료를 시도한 경험을 보고하는 바이다.

Keywords

References

  1. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105:14-20 https://doi.org/10.1542/peds.105.1.14
  2. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Mayock DE et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997;131:55-62 https://doi.org/10.1016/S0022-3476(97)70124-0
  3. Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997;336:605-10 https://doi.org/10.1056/NEJM199702273360902
  4. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998;101:325-34 https://doi.org/10.1542/peds.101.3.325
  5. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006;18:CD000399 https://doi.org/10.1002/14651858.CD000399.pub2
  6. Konduri GG. New approaches for persistent pulmonary hypertension of newborn. Clin Perinatol 2004;31:591-611 https://doi.org/10.1016/j.clp.2004.04.001
  7. Weinberger B, Weiss K, Heck DE, Laskin DL, Laskin JD. Pharmacologic therapy of persistent pulmonary hypertension of the newborn. Pharmacol Ther 2001;89:67-79 https://doi.org/10.1016/S0163-7258(00)00104-2
  8. Cassin S, Winikor I, Tod M, Philips J, Frisinger J, Jordan J et al. Effects of prostacyclin on the fetal pulmonary circulation. Pediatr Pharmacol (New York) 1981;1:197-207
  9. Eronen M, Pohjavuori M, Andersson S, Pesonen E, Raivio KO. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol 1997;18:3-7 https://doi.org/10.1007/s002469900099
  10. Santak B, Schreiber M, Kuen P, Lang D, Radermacher P. Prostacyclin aerosol in an infant with pulmonary hypertension. Eur J Pediatr 1995;154:233-5 https://doi.org/10.1007/BF01954279
  11. Santak B, Schreiber M, Kuen P, Lang D, Radermacher P. Prostacyclin aerosol in an infant with pulmonary hypertension. Eur J Pediatr 1995;154:233-5 https://doi.org/10.1007/BF01954279
  12. Soditt V, Aring C, Groneck P. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension. Intensive Care Med 1997; 23:1275-8 https://doi.org/10.1007/s001340050498
  13. de Wit C, von Bismarck P, Pohl U. Synergistic action of vasodilators that increase cGMP and cAMP in the hamster cremaster microcirculation. Cardiovasc Res 1994;28:1513-8 https://doi.org/10.1093/cvr/28.10.1513
  14. Hill LL, Pearl RG. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol 1999;86:1160-4 https://doi.org/10.1152/jappl.1999.86.4.1160
  15. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002;141:830-2 https://doi.org/10.1067/mpd.2002.129849
  16. Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension of the newborn. Cardiol Young 2003;13:361-3 https://doi.org/10.1017/S1047951103000726
  17. Aschner JL. New therapies for pulmonary hypertension in neonates and children. Pediatr Pulmonol Suppl 2004;26:132- 5
  18. Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001;103:544-8 https://doi.org/10.1161/01.CIR.103.4.544
  19. De Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as 'rescue' therapy for pulmonary hypertension of the neonate. Paediatr Anaesth 2007;17:394-5 https://doi.org/10.1111/j.1460-9592.2006.02104.x